A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: The U.S. Ecadotril Pilot Safety Study

American Heart Journal

Volumn 138, Issue 6 I, 1999, Pages 1140-1148

  O'Connor, C M ^a   Gattis, W A ^a   Gheorghiade, M ^a   Granger, C B ^a   Gilbert, J ^a   McKenney, J M ^a   Messineo, F C ^a   Burnett, J C ^a   Katz, S D ^a   Elkayam, U ^a   Kasper, E K ^a   Goldstein, S ^a   Cody, R J ^a   Massie, B M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SINORPHAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; FEMALE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; VERTIGO;

EID: 0032728452     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70081-5     Document Type: Article

References (16)

1. Francis GS, Benedict C, Johnstone D, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-30.
2. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the studies of left ventricular dysfunction (SOLVD) registry. J Am Coll Cardiol 1993;22(Suppl A):146A-53A.
3. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
4. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic response to peptide infusion. J Clin Invest 1986;78:1362-74.
5. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CGA, et al. Natriuretic peptide system in human heart failure. Circulation 1993;88:1004-9.
6. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet 1997;349:1307-10.
7. Deutsch A, Frishman WH, Sukenik D, Somer BG, Youssri A. Atrial natriuretic peptide and its potential role in pharmacotherapy. J Clin Pharmacol 1994;34:1133-47.
8. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
9. Davis KM, Fish LC, Elahi D, Clark BA, Minaker KL. Atrial natriuretic peptide levels in the prediction of congestive heart failure in the frail elderly. JAMA 1992;267:2625-9.
10. Abraham WT. New neurohormonal antagonists and atrial natriuretic peptide in the treatment of congestive heart failure. Coronary Artery Disease 1994;5:127-36.
11. Wegner M, Hirth-Dietrich C, Stasch JP. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Cardiovasc Res 1996;31:891-8.
12. Kahn JC, Patey M, Dubois-Rande JL, Merlet P, Castaigne A, Lim-Alexandre C, et al. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990;335:118-9.
13. Elsner D, Muntze A, Kromer EP, Riegger GAJ. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-8.
14. Kimmelstiel CD, Perrone R, Kilcoyne L, Souhrada J, Udelson J, Smith J, et al. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurhormonal activation in patients with congestive heart failure. Cardiology 1996;87:46-53.
15. Kentsch M, Otter W, Drummer C, Notges A, Gerzer R, MullerEsch G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol 1996;51:269-72.
16. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 1997;43:329-32.